Hendra virus facts
July 12, 2011 in Diseases, Conditions, SyndromesUniversity of Queensland researchers have produced batches of a monoclonal antibody, which may offer hope as a potential therapeutic for Hendra virus infection in humans.
The batches have been developed in UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN).
US Hendra virus expert Professor Chris Broder developed the antibody, which binds to a protein on the surface of virus particles, blocking entry to healthy human cells.
It is hoped that this will then allow the immune system to fight off the virus.
Hendra virus can be passed from bats to horses and in rare cases from horses to humans.
Dr. Alister Rodgers became the first person to receive the antibody treatment in a desperate bid to save his life.
He was working as a vet in Rockhampton when he came into contact with an infected horse and died in 2009.
The antibody was also given in 2010 to two people from the Sunshine Coast exposed to the Hendra virus.
Queensland Health sourced these antibody stocks from the US. It became clear a Queensland solution was needed to supply larger amounts of the antibody in case of future Hendra outbreaks.
In late 2010, Queensland Health provided 300,000AUD to AIBN to produce batches of the antibody for humans.
Last month AIBN received 180,000AUD in additional funding from Queensland Health to continue producing the antibody, adding to 40,000AUD received from the Alister Rodgers Memorial Fund early in 2011.
The Alister Rodgers Memorial Fund honours the life of Dr Rodgers and was established through The University of Queensland's School of Veterinary Science at the request of his family, to raise money for research into Hendra virus.
To date the AIBN has produced enough of the experimental antibody to treat up to 20 people, with further material to be produced later this year.
In addition, AIBN has produced the antibody for collaborators at the CSIRO Australian Animal Health Laboratory in Geelong for testing in animal trials.
Other CSIRO research is developing a vaccine for horses designed to prevent Hendra infection.
It is considered an experimental therapy because large-scale clinical testing has not been completed on the antibody.
It can only be used in emergency situations with approval from an ethics committee and representatives from the Therapeutic Goods Administration.
AIBN biotechnologist and antibody project overseer Dr Trent Munro said the institute had specialist equipment able to make high-quality batches of the antibody for humans.
Dr. Munro said the antibodies were created in a partner lab at the Uniformed Services University, Bethesda, Maryland in the US as part of a long-standing collaboration with the CSIRO.
The US lab was able to synthetically produce a portion of the virus and create an antibody that specifically recognised it, he said.
Antibodies can be produced using recombinant DNA technology, where the gene encoding the antibody is transferred to a cell that is able to express large amounts of the protein.
The US lab provided the cells that were producing the antibody and the AIBN developed a process to produce larger amounts of the antibody. AIBN did not produce any part of the Hendra virus.
For Hendra virus information, visit http://www.dpi.qld … 790_2900.htm
What is an antibody?
An antibody is a blood protein produced in response to and counteracting a specific antigen.
What diseases are antibody therapeutics used for?
Antibody therapeutics, also known as biologics, are now widely used for autoimmune diseases such as cancer, arthritis and psoriasis.
What does the Hendra virus antibody do?
The antibody binds to protein on the surface of Hendra virus particles, blocking entry to healthy human cells. The immune system is then able to fight off the virus.
How many people have been given the antibody treatment so far?
Three. All of these people were given an antibody treatment produced Walter Reed Army Medical Center in Washington DC. AIBN has since begun to produce an antibody.
Why is the antibody considered experimental an therapy?
The antibody has not been through human clinical trials. Clinical trials take years and involve large numbers of people. The small number of people exposed to the Hendra virus make clinical trials difficult at this stage.
Who makes the decision about giving people the antibody?
Decisions on administration of the antibody are handled by Queensland Health, specifically the Chief Health Officer and infectious disease experts at the Princess Alexandra Hospital. Any human treatment requires a special approval from an ethics committee and the Therapeutic Goods Administration.
How much of the antibody is available for humans?
A batch of more than 20g has been given to Queensland Health enough to treat up to 20 people.
How can the Hendra virus kill?
People develop a flu-like illness, including fevers and respiratory symptoms. The virus causes inflammation in the cells that form in the lining of the body's small blood vessels, particularly those in the brain and the lungs. The virus predominantly infects the cells which form the inside layer of blood vessels. Infection can cause small blood vessels, which supply oxygen to the body, to become obstructed.
Provided by
University of Queensland
-
Breakthrough in fight against Hendra virus
Oct 30, 2009 |
not rated yet |
0
-
Vaccine protects from deadly Hendra virus
May 17, 2011 |
not rated yet |
0
-
Minimising the spread of deadly Hendra virus
Mar 31, 2009 |
not rated yet |
0
-
Minimizing the spread of deadly Hendra virus
Apr 15, 2009 |
not rated yet |
0
-
Fresh horse death as Australia virus spreads
Jul 07, 2011 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
3 hours ago |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (3) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
Classical and Quantum Mechanics via Lie algebras
Apr 15, 2011
- More from Physics Forums - Independent Research
More news stories
World Health Assembly endorses new plan to increase global access to vaccines
Ministers of Health from 194 countries at the Sixty-fifth World Health Assembly today endorsed a landmark Global Vaccine Action Plan (GVAP), a roadmap to prevent millions of deaths by 2020 through more equitable access to ...
Diseases, Conditions, Syndromes
51 minutes ago |
not rated yet |
0
Physicians definitively links irritable bowel syndrome and bacteria in gut
An overgrowth of bacteria in the gut has been definitively linked to Irritable Bowel Syndrome in the results of a new Cedars-Sinai study which used cultures from the small intestine. This is the first study to use this "gold ...
Diseases, Conditions, Syndromes
1 hour ago |
not rated yet |
0
|
Study provides compelling evidence for an effective new treatment for tinnitus
According to new research, a multidisciplinary approach to treating tinnitus that combines cognitive behaviour therapy with sound-based tinnitus retraining therapy is significantly more effective than currently available ...
Diseases, Conditions, Syndromes
17 hours ago |
not rated yet |
0
Infections may be deadly for many dialysis patients
An infection called peritonitis commonly arises in the weeks before many dialysis patients die, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings sugges ...
Diseases, Conditions, Syndromes
18 hours ago |
not rated yet |
0
Obese patients face increased risk of kidney damage after heart surgery
Oxidative stress may put obese patients at increased risk of developing kidney damage after heart surgery, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Effect ...
Diseases, Conditions, Syndromes
18 hours ago |
not rated yet |
0
Inherited DNA change explains overactive leukemia gene
A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.
Cancer may require simpler genetic mutations than previously thought
Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...
Implantable pain disk may help those with cancer
An estimated 3.5 million cancer patients around the globe are in severe pain from their disease, but many get no relief.
In Spain, 70 percent of women use contraceptives during their first sexual encounter
Contraceptive use in Spain during the first sexual encounter is similar to other European countries. However, there are some geographical differences between Spanish regions: women in Murcia use contraceptives ...
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
First study to suggest that the immune system may protect against Alzheimer's changes in humans
Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.